吡柔比星在非肌层浸润性膀胱癌二次电切术中的应用  

Effect of pirarubicin in repeated transurethral resection of non-muscle invasive bladder cancer

作　　者：曾毅刚[1] 邱建新[1] 

机构地区：[1]上海交通大学附属第一人民医院泌尿外科,上海200080

出　　处：《世界临床药物》2012年第11期649-652,共4页World Clinical Drug

摘　　要：膀胱癌是常见的泌尿系统恶性肿瘤之一,行常规经尿道膀胱癌电切术(TURBT)加术后膀胱内化疗药物灌注,复发率及进展率较高。目前主张在行经尿道膀胱癌电切术后4周内再次行该术式,但仍有较大盲目性。吡柔比星具有抗癌谱广、被肿瘤细胞选择性吸收后在膀胱镜下形成橙色染色区等特性,用于膀胱癌治疗尤其是在二次电切术治疗中,不但能杀死肿瘤细胞,还具有示踪作用,可作为膀胱灌注药物的首选,临床应用前景广。Bladder cancer is a common malignant tumor in urinary system.After conventional transurethral bladder tumor resection（TURBT） combined with post treatment of intravesical chemotherapy drug perfusion,the rates of cancer relapse and progress are still high.It suggested a secondary TURBT within 4 weeks after the first operation,but there are still certain problems.Pirarubicin can kill the tumor cells and can trace where they are.It has many advantages,such as wide anticancer spectrum,selectively absorbed by tumor cells and formed orange stained region in the cystoscope.This paper reviews the advantages of bladder cancer treatment,especially in second time TURBT.As a preferred bladder perfusion drug,pirarubicin has a broad application prospect.

关 键 词：膀胱癌 吡柔比星 二次经尿道膀胱癌电切术 

分 类 号：R979.1[医药卫生—药品] R737.14[医药卫生—药学]